Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2001-08-23
2002-11-12
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252100, C514S255060, C514S307000, C514S311000, C514S357000, C514S365000, C514S381000, C514S394000, C514S400000, C514S406000, C514S419000, C514S427000, C514S461000, C514S866000
Reexamination Certificate
active
06479493
ABSTRACT:
TECHNICAL FIELD
This invention relates to the treatment of type I diabetes.
BACKGROUND OF THE INVENTION
Type 1 or Insulin Dependent Diabetes Mellitus (IDDM) is estimated to affect 675,000 people in the United States. This represents 0.3% of the total U.S. population, with an estimated 30,000 new cases diagnosed each year. Complications of diabetes impair the longevity and quality of life, and include atherosclerotic heart disease, gangrene and stroke, as well as diabetic retinopathy, neuropathy and nephropathy. Within 15 years after the onset of diabetes, retinopathy may be observed in 97% of Type 1 diabetics. Today diabetic retinopathy remains the leading cause of blindness in the U.S. and patients with diabetes are 25 times more likely to develop blindness than the general population.
Symptoms of diabetic neuropathy have been observed in 54% of Type 1 patients studied. Patients present with symptoms ranging from peripheral sensory-deficits (pins and needles/carpal tunnel syndrome) to autonomic neuropathy resulting in bladder and bowel dysfunction. Type 1 diabetes is also responsible for a large proportion of the patients on renal dialysis, the result of diabetes-induced end stage renal disease. More than 40% of Type 1 patients who have had diabetes for more than 20 years have diabetic nephropathy. The prevalence of myocardial infarction, angina and stroke is 2-3 times greater than in non-diabetics, and the Type 1 diabetic's life span is shortened by about 15 years. The estimated total cost of Type 1 diabetes in the United States (medical expenses, lost wages etc.) is greater than $20 billion per year.
Type I diabetes actually begins before the clinical manifestations of the disease. It starts with the progressive destruction of beta cells in the pancreas. These cells normally produce insulin. The reduction of insulin response to glucose can be measured during this period, however. Ultimately there is massive (>90%) destruction of beta cells in the islets of Langer hans. During the early stages of the disease and beyond, type I diabetes is characterized by the infiltration of pancreatic islets by macrophages and lymphocytes (helper and killer). The macrophage infiltration is believed to prompt the infiltration of small lymphocytes. While clinicians understand the potential for a drug that can address macrophage involvement early in the disease, no safe therapies have yet been found. Current treatment involves daily frequent injections of insulin. However, this can lead to side effects such as hypoglycemic shock.
Thus, there is an urgent, unmet need for safe and effective drug therapies for type I diabetes, particularly a therapy that can intervene in the early stages of the disease to treat macrophage infiltration and prevent subsequent beta cell damage by macrophages.
SUMMARY OF THE INVENTION
This invention represents a novel therapy for treating patients (e.g., humans or companion animals) with type I diabetes without the substantial side effects of prior pharmaceutical approaches. Specifically, this invention involves the administration of an inhibitor of phosphodiesterase 2 (“PDE2”) to a mammal in need of treatment for type I diabetes. Preferably, that inhibitor also inhibits phosphodiesterase 5 (“PDE5”). In narrower aspects of this invention, this invention involves the administration of compounds of Formula I below to a mammal in need of treatment for type I diabetes.
As explained below, compounds that inhibit PDE2 can cause activated macrophages to undergo apoptosis.
REFERENCES:
patent: 3031450 (1962-04-01), Fischer et al.
patent: 3161654 (1964-12-01), Shen
patent: 3312730 (1967-04-01), Winter et al.
patent: 3322755 (1967-05-01), Roch et al.
patent: 3325358 (1967-06-01), Winter et al.
patent: 3532752 (1970-10-01), Shen
patent: 3642785 (1972-02-01), Shen et al.
patent: 3647858 (1972-03-01), Hinkley et al.
patent: 3654349 (1972-04-01), Shen et al.
patent: 3692651 (1972-09-01), Sletzinger et al.
patent: 3692825 (1972-09-01), Conn
patent: 3737455 (1973-06-01), Shen et al.
patent: 3851063 (1974-11-01), Shen et al.
patent: 3860636 (1975-01-01), Shen et al.
patent: 4307114 (1981-12-01), Dvornik et al.
patent: 4402979 (1983-09-01), Shen et al.
patent: 4423074 (1983-12-01), Dvornik et al.
patent: 4423075 (1983-12-01), Dvornik et al.
patent: 4880810 (1989-11-01), Lowe, III
patent: 4885301 (1989-12-01), Coates
patent: 5298525 (1994-03-01), Yoon et al.
patent: 5401774 (1995-03-01), Pamukcu et al.
patent: 5470873 (1995-11-01), Yoon
patent: 5488055 (1996-01-01), Kumar et al.
patent: 5527896 (1996-06-01), Wigler et al.
patent: 5602019 (1997-02-01), Beavo et al.
patent: 5602171 (1997-02-01), Tang et al.
patent: 5614530 (1997-03-01), Kumar et al.
patent: 5614627 (1997-03-01), Takase et al.
patent: 5708022 (1998-01-01), Bastos et al.
patent: 5776752 (1998-07-01), Beavo et al.
patent: 5789553 (1998-08-01), Beavo et al.
patent: 5798374 (1998-08-01), Tang et al.
patent: 5800987 (1998-09-01), Beavo et al.
patent: 5852035 (1998-12-01), Pamukcu et al.
patent: 5858694 (1999-01-01), Piazza et al.
patent: 5861396 (1999-01-01), Nieöhner et al.
patent: 5874440 (1999-02-01), Pamukcu et al.
patent: 5883110 (1999-03-01), Tang et al.
patent: 5885834 (1999-03-01), Epstein
patent: 5902827 (1999-05-01), Pamukcu et al.
patent: 5922595 (1999-07-01), Fisher et al.
patent: 5942520 (1999-08-01), Pamukcu et al.
patent: 5948911 (1999-09-01), Pamukcu et al.
patent: 5958982 (1999-09-01), Pamukcu et al.
patent: 5990117 (1999-11-01), Pamukcu et al.
patent: 5998463 (1999-12-01), Hulin et al.
patent: 6008215 (1999-12-01), Flockerzi
patent: 6015677 (2000-01-01), Beavo et al.
patent: 6034099 (2000-03-01), Pamukcu et al.
patent: 6037345 (2000-03-01), Pamukcu et al.
patent: 6046199 (2000-04-01), Pamukcu et al.
patent: 6046206 (2000-04-01), Pamukcu et al.
patent: 6046216 (2000-04-01), Piazza et al.
patent: 6060477 (2000-05-01), Piazza et al.
patent: 6063818 (2000-05-01), Sperl et al.
patent: 6066634 (2000-05-01), Sperl et al.
patent: 6069240 (2000-05-01), Wigler et al.
patent: 6071934 (2000-06-01), Sperl et al.
patent: 6077842 (2000-06-01), Pamukcu et al.
patent: 6080540 (2000-06-01), Wigler et al.
patent: 6080742 (2000-06-01), Germann et al.
patent: 6080772 (2000-06-01), Tang et al.
patent: 6100025 (2000-08-01), Wigler et al.
patent: 6107295 (2000-08-01), Rochus et al.
patent: 6124303 (2000-09-01), Pamukcu et al.
patent: 6133271 (2000-10-01), Pamukcu et al.
patent: 6143746 (2000-11-01), Daugan et al.
patent: 6143759 (2000-11-01), Flockerzi
patent: 6143765 (2000-11-01), Tang et al.
patent: 6143777 (2000-11-01), Jonas et al.
patent: 6169090 (2001-01-01), Dyke et al.
patent: 6174884 (2001-01-01), Haning et al.
patent: 6187779 (2001-02-01), Pamukcu et al.
patent: 6200771 (2001-03-01), Liu et al.
patent: 6200980 (2001-03-01), Piazza et al.
patent: 6207666 (2001-03-01), Piazza et al.
patent: 6211177 (2001-04-01), Sperl et al.
patent: 6211220 (2001-04-01), Pamukcu et al.
patent: 6232312 (2001-05-01), Pamukcu et al.
patent: 6235742 (2001-05-01), Bell et al.
patent: 6235776 (2001-05-01), Pamukcu et al.
patent: 6235782 (2001-05-01), Pamukcu et al.
patent: 6239136 (2001-05-01), Pamukcu et al.
patent: 6251904 (2001-06-01), Bunnage et al.
patent: 6255303 (2001-07-01), Sterk et al.
patent: 6255456 (2001-07-01), Fisher et al.
patent: 6258833 (2001-07-01), Martins et al.
patent: 6268372 (2001-07-01), Pamukcu et al.
patent: 0 349 239 (1990-01-01), None
patent: 0 395 328 (1990-10-01), None
patent: 0 428 268 (1991-05-01), None
patent: 0 463 756 (1992-01-01), None
patent: 0 293 063 (1992-03-01), None
patent: 0 526 004 (1993-02-01), None
patent: 0 351 058 (1993-06-01), None
patent: 0 347 146 (1993-09-01), None
patent: 0 352 960 (1994-10-01), None
patent: 0 722 943 (1996-01-01), None
patent: 0 722 944 (1996-01-01), None
patent: 1 074 258 (2001-04-01), None
patent: 807826 (1959-01-01), None
patent: 2 063 249 (1981-06-01), None
patent: SHO 61-106521 (1986-05-01), None
patent: Hei 8-311035 (1996-11-01), None
patent: WO 93/07149 (1993-04-01), None
patent: WO 94/29277 (1994-11-01), None
patent: WO 97/03675 (1997-02-01), None
patent
Alila Hector W.
Earle Keith A.
Thompson W. Joseph
Whitehead Clark M.
Cell Pathways Inc.
Stevenson Robert W.
Weddington Kevin E.
LandOfFree
Methods for treatment of type I diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of type I diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of type I diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2935171